Health:
In clinical studies over the past 20 years, our partnered Immunitor oral pill immunotherapies have consistently proven the science and demonstrated superior safety and efficacy in diseases such as cancers, tuberculosis, HIV/AIDS, hepatitis.In many cases where other treatments have failed.
Key Capital is now working with Immunitor towards FDA product registrations and commercialization that will contribute to a better healthcare future.
New leadership for Key Capital following the sad passing of founder, Chairman and CEO, Peter Boonen.
NEW YORK, NY, April 29, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises it is evident the COVID situation in India is a humanitarian catastrophe, and that although the head of WHO states it is “beyond heartbreaking”, it appears that the COVID crisis in India will unfortunately get a lot worse.
NEW YORK, NY, April 26, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that Immunitor, its Licensing partner, continues to receive favorable reports from people in Asian and African countries using the Immunitor HAP-V+ Immune Supplement in cases of respiratory infections.
